JPMorgan Chase & Co. lifted its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 28.0% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 640,475 shares of the biotechnology company’s stock after purchasing an additional 139,976 shares during the quarter. JPMorgan Chase & Co. owned about 1.48% of United Therapeutics worth $76,065,000 as of its most recent filing with the SEC.

Several other large investors have also recently modified their holdings of UTHR. US Bancorp DE grew its holdings in shares of United Therapeutics by 3.2% during the 2nd quarter. US Bancorp DE now owns 4,175 shares of the biotechnology company’s stock worth $541,000 after purchasing an additional 128 shares during the period. Eagle Global Advisors LLC purchased a new stake in shares of United Therapeutics during the 2nd quarter worth about $206,000. Great West Life Assurance Co. Can grew its holdings in shares of United Therapeutics by 8.9% during the 2nd quarter. Great West Life Assurance Co. Can now owns 121,115 shares of the biotechnology company’s stock worth $15,696,000 after purchasing an additional 9,948 shares during the period. World Asset Management Inc grew its holdings in shares of United Therapeutics by 3.1% during the 2nd quarter. World Asset Management Inc now owns 2,973 shares of the biotechnology company’s stock worth $386,000 after purchasing an additional 88 shares during the period. Finally, Pictet Asset Management Ltd. lifted its position in United Therapeutics by 6.3% during the 2nd quarter. Pictet Asset Management Ltd. now owns 95,711 shares of the biotechnology company’s stock worth $11,571,000 after acquiring an additional 5,700 shares in the last quarter. Institutional investors and hedge funds own 99.94% of the company’s stock.

United Therapeutics Corporation (UTHR) opened at $134.17 on Wednesday. United Therapeutics Corporation has a 52-week low of $112.01 and a 52-week high of $169.89. The stock has a market capitalization of $5,791.15, a P/E ratio of 11.82 and a beta of 1.42.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, October 25th. The biotechnology company reported $6.27 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $4.01 by $2.26. United Therapeutics had a return on equity of 26.24% and a net margin of 30.50%. The company had revenue of $445.50 million for the quarter, compared to analyst estimates of $426.43 million. During the same period in the prior year, the company posted $4.23 EPS. United Therapeutics’s quarterly revenue was up 9.1% on a year-over-year basis. research analysts predict that United Therapeutics Corporation will post 12.45 EPS for the current year.

Several equities analysts recently commented on UTHR shares. Oppenheimer reissued a “buy” rating on shares of United Therapeutics in a research report on Friday, September 8th. ValuEngine raised United Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, October 2nd. BidaskClub raised United Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday. Zacks Investment Research raised United Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, October 9th. Finally, HC Wainwright reissued a “hold” rating and set a $95.00 price target on shares of United Therapeutics in a research report on Thursday, October 26th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and three have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $136.10.

In other United Therapeutics news, CEO Martine A. Rothblatt sold 1,274 shares of the company’s stock in a transaction that occurred on Thursday, September 21st. The stock was sold at an average price of $116.07, for a total value of $147,873.18. Following the transaction, the chief executive officer now directly owns 2,343 shares of the company’s stock, valued at approximately $271,952.01. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Martine A. Rothblatt sold 1,232 shares of the company’s stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $133.32, for a total value of $164,250.24. Following the completion of the transaction, the chief executive officer now directly owns 2,301 shares in the company, valued at $306,769.32. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 23,900 shares of company stock worth $2,919,517. 7.80% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: “United Therapeutics Corporation (UTHR) Holdings Increased by JPMorgan Chase & Co.” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright law. The legal version of this article can be read at https://www.thecerbatgem.com/2017/12/06/united-therapeutics-corporation-uthr-holdings-increased-by-jpmorgan-chase-co.html.

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Stock Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related stocks with our FREE daily email newsletter.